Novo Integrated Sciences, Inc. Engages Investor Acquisition Advisors
Bellevue, Washington--(Newsfile Corp. - November 18, 2020) - Novo Integrated Sciences, Inc. (OTCQB: NVOS), a provider of multi-dimensional primary healthcare services and products in Canada and the U.S. (the "Company"), announces it has engaged Investor Acquisition Advisors to enhance the investor community's market awareness of Novo Integrated Sciences through Investor Acquisition Advisors' expertise and its proprietary investor acquisition equity research and digital marketing platform.
Mr. Robert Mattacchione, Novo Integrated Sciences' CEO and Board Chairman, stated, "We are very pleased to have Michael and Jon spearheading our initiative to increase U.S. market investor community awareness in alignment with our plans for up-list to the NASDAQ Capital Market. Healthcare in today's COVID-19 pandemic era is undergoing massive change in how the patient interacts with their clinician and licensed providers to diagnose, improve, and sustain their health and wellness. With such disruptive change in the healthcare sector, it is imperative we consistently keep the investor community aware of the business growth initiatives being pursued by the Company through the integration of medical technology, advanced therapeutics and rehabilitative science."
As reported on October 19, 2020, the Company has submitted an application to up-list its common stock to the NASDAQ Capital Market. Acceptance for listing the Company's shares of common stock is subject to approval and satisfaction of several factors, including minimum listing requirements for the NASDAQ Capital Market. The Company is optimistic that it can satisfy all applicable listing requirements; however, there is no assurance that its application will be approved.
About Novo Integrated Sciences, Inc.
Novo Integrated Sciences, Inc. is a U.S. based Nevada corporation which owns Canadian and U.S. subsidiaries that deliver, or intend to deliver, multidisciplinary primary health care related services and products through the integration of medical technology, advanced therapeutics and rehabilitative science.
Currently, the Company's revenue is generated solely through its wholly owned Canadian subsidiary, Novo Healthnet Limited ("NHL"), which provides our services and products through both clinic and eldercare related operations.
NHL's team of multidisciplinary primary health care clinicians and practitioners provide assessment, diagnosis, treatment, pain management, rehabilitation, education and primary prevention for a wide array of orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics including pediatric, adult, and geriatric populations through NHL's 16 corporate-owned clinics, a contracted network of 102 affiliate clinics, and 220 eldercare related long-term care homes, retirement homes, and community-based locations in Canada.
Additionally, we continue to expand our patient care philosophy of maintaining an on-going continuous connection with our patient community, beyond the traditional confines of brick and mortar facilities, by extending oversight of patient diagnosis, care and monitoring, directly through various Medical Technology Platforms either in-use or under development.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Novo Integrated Sciences' filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond Novo Integrated Sciences' control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo Integrated Sciences' current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo Integrated Sciences assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.
Chris David, President
Novo Integrated Sciences, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68413